These discoveries not only elucidate a novel mechanism underlying liver fibrosis caused by schistosomiasis but also identify the miR-383-5p/PRDX3 pathway as a promising therapeutic target for antifibrotic interventions. Here, PRDX3 is linked to schistosomiasis.